

# Stuart J McGurnaghan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3972093/publications.pdf>

Version: 2024-02-01

43  
papers

1,590  
citations

394421

19  
h-index

330143

37  
g-index

50  
all docs

50  
docs citations

50  
times ranked

3308  
citing authors

#	ARTICLE	IF	CITATIONS
1	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. <i>Diabetologia</i> , 2022, 65, 159-172.	6.3	12
2	Effect of serum sample storage temperature on metabolomic and proteomic biomarkers. <i>Scientific Reports</i> , 2022, 12, 4571.	3.3	11
3	<i>PRF1</i> mutation alters immune system activation, inflammation, and risk of autoimmunity. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1332-1340.	3.0	13
4	Quantitative levels of serum <i>N</i>-glycans in type 1 diabetes and their association with kidney disease. <i>Glycobiology</i> , 2021, 31, 613-623.	2.5	6
5	Novel Linkage Peaks Discovered for Diabetic Nephropathy in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 986-995.	0.6	5
6	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 82-93.	11.4	251
7	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021, 19, 51.	5.5	41
8	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 1309-1319.	6.3	5
9	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021, 64, 1320-1331.	6.3	19
10	Microvascular disease in diabetes and severe COVID-19 outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 201.	11.4	0
11	Insulin resistance-associated genetic variants in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107842.	2.3	8
12	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study. <i>BMC Medicine</i> , 2021, 19, 149.	5.5	26
13	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 2001-2011.	6.3	22
14	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021, 44, 2010-2017.	8.6	8
15	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 901-907.	8.6	16
16	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. <i>Diabetes Care</i> , 2021, 44, 390-398.	8.6	55
17	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 788-798.	6.3	31
18	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. <i>Diabetologia</i> , 2020, 63, 636-647.	6.3	22

#	ARTICLE	IF	CITATIONS
19	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003374.	8.4	61
20	Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. <i>Diabetes Care</i> , 2020, 43, 734-742.	8.6	22
21	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004-2017. <i>Diabetologia</i> , 2020, 63, 1626-1636.	6.3	6
22	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€˜s Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€˜s Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 IgBT / Overlock 10	8.6	13
23	Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. <i>Science Advances</i> , 2020, 6, eaax0301.	10.3	90
24	Title is missing!. , 2020, 17, e1003374.		0
25	Title is missing!. , 2020, 17, e1003374.		0
26	Title is missing!. , 2020, 17, e1003374.		0
27	Title is missing!. , 2020, 17, e1003374.		0
28	Title is missing!. , 2020, 17, e1003374.		0
29	Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002945.	8.4	12
30	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2000-2016.	6.1	135
31	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. <i>BMC Medicine</i> , 2019, 17, 165.	5.5	43
32	Biomarker panels associated with progression of renal disease in type 1 diabetes. <i>Diabetologia</i> , 2019, 62, 1616-1627.	6.3	41
33	Glycaemic control trends in people with type 1 diabetes in Scotland 2004-2016. <i>Diabetologia</i> , 2019, 62, 1375-1384.	6.3	45
34	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. <i>Diabetologia</i> , 2019, 62, 621-632.	6.3	33
35	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. <i>Diabetic Medicine</i> , 2019, 36, 718-725.	2.3	46
36	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004-2013. <i>Diabetic Medicine</i> , 2018, 35, 99-106.	2.3	19

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. <i>Diabetes Care</i> , 2018, 41, 341-347.	8.6	92
38	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 79-87.	8.6	75
39	Amputation-free survival in 17,353 people at high risk for foot ulceration in diabetes: a national observational study. <i>Diabetologia</i> , 2018, 61, 2590-2597.	6.3	55
40	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. <i>Circulation</i> , 2018, 138, 2774-2786.	1.6	139
41	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. <i>BMC Nephrology</i> , 2017, 18, 163.	1.8	63
42	Modelling cumulative exposure for inference about drug effects in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1527-1533.	1.9	7
43	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). <i>International Journal of Epidemiology</i> , 2016, 46, dyw152.	1.9	15